Pancreatic Cancer Early Detection (PRECEDE) Consortium
The Brenden-Colson Center for Pancreatic Care is proud to be part of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international network of experts working together to improve survival for people at risk of pancreatic cancer.
Through this unique collaboration and data-sharing effort, researchers are advancing strategies for:
- Early detection
- Ongoing surveillance
- Risk modeling
- Prevention for those at higher risk
PRECEDE’s goal is to increase the 5-year survival rate for pancreatic cancer to 50% within the next 10 years.
Program Site Leader
Cancer Biology
Imaging
Gastroenterology
Biospecimens
Genetic Counseling
Want to join the PRECEDE Consortium?
The PRECEDE Consortium is the largest high-risk patient cohort!
You may qualify for PRECEDE if:
- You or a family member has a history of pancreatic cancer
Our team would be glad to meet with you to discuss eligibility and next steps.
If you choose to participate in this study, your involvement may include:
- Blood samples: Providing a small blood sample at each clinic visit (about 1–2 times per year) and at any follow-up if imaging or lab results show something that needs closer evaluation.
- Health history: Sharing information about your medical and family history.
- Medical records: Allowing our team to access your medical records and results from routine care (such as genetic testing or imaging studies).
- Tissue donation: If you are ever diagnosed with pancreatic cancer, you may be asked to donate a small amount of extra tissue collected during a clinical biopsy or surgery.
These samples and information help create a vital research resource to improve early detection and prevention for future patients and families.
If you believe you may be eligible to join the PRECEDE Consortium, talk with your primary care provider about a referral to OHSU's Pancreatic High Risk Clinic.
For questions or more information, please contact us at: 📞 (503) 494-4373